Analyst Upgrades: Facebook Inc, FireEye Inc, and Juno Therapeutics Inc

Analysts upwardly revised their ratings on Facebook Inc (FB), FireEye Inc (FEYE), and Juno Therapeutics Inc (JUNO)

Aug 18, 2015 at 8:55 AM
facebook X logo linkedin

Analysts are weighing in today on social network Facebook Inc (NASDAQ:FB), cybersecurity firm FireEye Inc (NASDAQ:FEYE), and drugmaker Juno Therapeutics Inc (NASDAQ:JUNO). Here's a quick roundup of today's bullish brokerage notes on FB, FEYE, and JUNO.

  • FB saw its price target raised to $120 from $105 at MKM Partners. The bullish brokerage attention is par for the course, as 27 of 29 analysts rate Facebook Inc a "buy" or better -- with not a single "sell" recommendation in sight -- while its consensus 12-month price target of $111.27 sits in uncharted territory. The optimism contrasts sharply with what we're seeing in the options pits, where the stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.58 ranks in the 90th percentile of its annual range. On the charts, FB has advanced over 20% year-to-date to trade at $93.93, and less than one month ago touched a record high of $99.24. A capitulation among the bearish holdouts in options land could provide another catalyst higher.

  • Imperial Capital boosted its opinion on FEYE to "outperform" from "in-line," and raised its price target to $55 from $45.50. As such, the shares are pointed 1.2% higher ahead of the bell, and could add to their more than 38% year-to-date gain, as of Monday's close at $43.65. As with FB, FireEye Inc faces skepticism among option traders. The stock's 10-day ISE/CBOE/PHLX put/call volume ratio rests at a 12-month high of 0.87. Should these bears begin to hit the exits, FEYE could catch a tailwind.

  • FBR Capital Markets initiated coverage on JUNO with an "outperform" rating, despite the stock being down 20.4% year-to-date. Thanks to the bullish attention, though, the security is poised to pop nearly 2% at the open. On the sentiment front, positivity is nothing new for Juno Therapeutics Inc -- among the brokerage bunch, at least. Eighty percent of covering analysts consider the shares worthy of a "strong buy" rating, with not a single "sell" assessment to be found. Plus, JUNO's consensus 12-month price target of $63.80 stands at a 53.5% premium to last night's settlement at $41.56.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI